 Calcium Channel Blockers
"Calcium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools. Since they are inducers of vascular and other smooth muscle relaxation, they are used in the drug therapy of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
| Descriptor ID |
D002121
|
| MeSH Number(s) |
D27.505.519.562.249 D27.505.954.411.192
|
| Concept/Terms |
Calcium Channel Blockers- Calcium Channel Blockers
- Calcium Antagonists, Exogenous
- Exogenous Calcium Blockaders
- Blockaders, Exogenous Calcium
- Calcium Blockaders, Exogenous
- Calcium Channel Blocking Drugs
- Exogenous Calcium Inhibitors
- Inhibitors, Exogenous Calcium
- Calcium Inhibitors, Exogenous
- Exogenous Calcium Antagonists
- Antagonists, Exogenous Calcium
- Channel Blockers, Calcium
- Blockers, Calcium Channel
|
Below are MeSH descriptors whose meaning is more general than "Calcium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Calcium Channel Blockers".
This graph shows the total number of publications written about "Calcium Channel Blockers" by people in this website by year, and whether "Calcium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1983 | 1 | 0 | 1 | | 1984 | 2 | 2 | 4 | | 1985 | 3 | 1 | 4 | | 1987 | 0 | 1 | 1 | | 1989 | 1 | 1 | 2 | | 1990 | 3 | 0 | 3 | | 1991 | 4 | 2 | 6 | | 1992 | 0 | 1 | 1 | | 1993 | 1 | 4 | 5 | | 1994 | 1 | 3 | 4 | | 1995 | 2 | 4 | 6 | | 1996 | 8 | 4 | 12 | | 1997 | 7 | 4 | 11 | | 1998 | 4 | 9 | 13 | | 1999 | 6 | 2 | 8 | | 2000 | 3 | 6 | 9 | | 2001 | 5 | 4 | 9 | | 2002 | 3 | 2 | 5 | | 2003 | 3 | 10 | 13 | | 2004 | 5 | 7 | 12 | | 2005 | 4 | 6 | 10 | | 2006 | 3 | 7 | 10 | | 2007 | 3 | 5 | 8 | | 2008 | 2 | 6 | 8 | | 2009 | 0 | 3 | 3 | | 2010 | 3 | 5 | 8 | | 2011 | 3 | 7 | 10 | | 2012 | 0 | 2 | 2 | | 2013 | 5 | 0 | 5 | | 2014 | 1 | 3 | 4 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 4 | 4 | | 2018 | 1 | 3 | 4 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Calcium Channel Blockers" by people in Profiles.
-
Cunningham PN, Chapman AB. The future of pharmacogenetics in the treatment of hypertension. Pharmacogenomics. 2019 02; 20(3):129-132.
-
Brennan MB, Guihan M, Budiman-Mak E, Kang H, Lobo JM, Sutherland BL, Emanuele N, Huang ES, Sohn MW. Increasing SBP variability is associated with an increased risk of developing incident diabetic foot ulcers. J Hypertens. 2018 11; 36(11):2177-2184.
-
Omboni S, Kario K, Bakris G, Parati G. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment. J Hypertens. 2018 04; 36(4):720-733.
-
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nat Rev Dis Primers. 2018 03 22; 4:18014.
-
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. J Am Heart Assoc. 2018 01 04; 7(1).
-
Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
-
Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol. 2018 04; 218(4):390-400.
-
Koren D, Grove JCR, Wei W. Cross-compartmental Modulation of Dendritic Signals for Retinal Direction Selectivity. Neuron. 2017 Aug 16; 95(4):914-927.e4.
-
Galaz-Montoya M, Wright SJ, Rodriguez GJ, Lichtarge O, Wensel TG. ß2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem. 2017 06 16; 292(24):9967-9974.
-
Chellan B, Reardon CA, Getz GS, Hofmann Bowman MA. Enzymatically Modified Low-Density Lipoprotein Promotes Foam Cell Formation in Smooth Muscle Cells via Macropinocytosis and Enhances Receptor-Mediated Uptake of Oxidized Low-Density Lipoprotein. Arterioscler Thromb Vasc Biol. 2016 06; 36(6):1101-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|